| Dr Svetlana M Grinblat, MD | |
|
80th St & 41st Ave, Elmhurst, NY 11373-1329 | |
| (718) 334-5970 | |
| (718) 334-5958 |
| Full Name | Dr Svetlana M Grinblat |
|---|---|
| Gender | Female |
| Speciality | General Acute Care Hospital |
| Location | 80th St & 41st Ave, Elmhurst, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316023476 | NPI | - | NPPES |
| 00246075 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0105X | Pathology - Clinical Pathology/laboratory Medicine | 163163 (New York) | Secondary |
| 282N00000X | General Acute Care Hospital | 163163 (New York) | Primary |
| Entity Name | New York City Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548208127 PECOS PAC ID: 4183535305 Enrollment ID: O20040322001521 |
News Archive
Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.
Improving the predictions of survival indicators in breast cancer patients through artificial intelligence and probabilistic modeling tools is the goal of ModGraProDep, an innovative system presented in a study published in the journal Artificial Intelligence in Medicine.
Consumers decide whether to use mail-in genetic tests based on both rational and emotional reasons, a finding that adds to a growing body of health-care behavior research on information seeking and avoidance, according to researchers at the University of California, Riverside.
A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Svetlana M Grinblat, MD 7901 Broadway, Managed Care, D1-01, Elmhurst, NY 11373-1329 Ph: (718) 334-1921 | Dr Svetlana M Grinblat, MD 80th St & 41st Ave, Elmhurst, NY 11373-1329 Ph: (718) 334-5970 |
News Archive
Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.
Improving the predictions of survival indicators in breast cancer patients through artificial intelligence and probabilistic modeling tools is the goal of ModGraProDep, an innovative system presented in a study published in the journal Artificial Intelligence in Medicine.
Consumers decide whether to use mail-in genetic tests based on both rational and emotional reasons, a finding that adds to a growing body of health-care behavior research on information seeking and avoidance, according to researchers at the University of California, Riverside.
A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.
› Verified 8 days ago